These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29899045)

  • 21. Patterns of Kidney Function Decline Associated with APOL1 Genotypes: Results from AASK.
    Tin A; Grams ME; Estrella M; Lipkowitz M; Greene TH; Kao WHL; Li L; Appel LJ
    Clin J Am Soc Nephrol; 2016 Aug; 11(8):1353-1359. PubMed ID: 27230965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. APOL1 Genotype and Glomerular and Tubular Kidney Injury in Women With HIV.
    Jotwani V; Shlipak MG; Scherzer R; Parekh RS; Kao WH; Bennett M; Cohen MH; Nowicki M; Sharma A; Young M; Tien PC; Parikh CR; Estrella MM
    Am J Kidney Dis; 2015 Jun; 65(6):889-98. PubMed ID: 25921719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1.
    Lertdumrongluk P; Streja E; Rhee CM; Moradi H; Chang Y; Reddy U; Tantisattamo E; Kalantar-Zadeh K; Kopp JB
    Cardiorenal Med; 2019; 9(4):212-221. PubMed ID: 30995638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between
    Jiang L; Liu G; Oeser A; Ihegword A; Dickson AL; Daniel LL; Hung AM; Cox NJ; Chung CP; Wei WQ; Stein CM; Feng Q
    Elife; 2023 Oct; 12():. PubMed ID: 37882666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FGF23 Concentration and
    Chan GC; Divers J; Russell GB; Langefeld CD; Wagenknecht LE; Hsu FC; Xu J; Smith SC; Palmer ND; Hicks PJ; Bowden DW; Register TC; Ma L; Carr JJ; Freedman BI
    Diabetes Care; 2018 Jan; 41(1):178-186. PubMed ID: 29113983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Testing and Disclosing Ancestry-Specific Genetic Risk for Kidney Failure on Patients and Health Care Professionals: A Randomized Clinical Trial.
    Nadkarni GN; Fei K; Ramos MA; Hauser D; Bagiella E; Ellis SB; Sanderson S; Scott SA; Sabin T; Madden E; Cooper R; Pollak M; Calman N; Bottinger EP; Horowitz CR
    JAMA Netw Open; 2022 Mar; 5(3):e221048. PubMed ID: 35244702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease.
    Ma L; Langefeld CD; Comeau ME; Bonomo JA; Rocco MV; Burkart JM; Divers J; Palmer ND; Hicks PJ; Bowden DW; Lea JP; Krisher JO; Clay MJ; Freedman BI
    Kidney Int; 2016 Aug; 90(2):389-395. PubMed ID: 27157696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease.
    Hung AM; Assimon VA; Chen HC; Yu Z; Vlasschaert C; Triozzi JL; Chan H; Wheless L; Wilson O; Shah SC; Mack T; Thompson T; Matheny ME; Chandrasekar S; Mozaffari SV; Chung CP; Tsao P; Susztak K; Siew ED; Estrada K; Gaziano JM; Graham RR; Tao R; Hoek M; Robinson-Cohen C; Green EM; Bick AG;
    J Am Soc Nephrol; 2023 Nov; 34(11):1889-1899. PubMed ID: 37798822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Expanding Role of APOL1 Risk in Chronic Kidney Disease and Cardiovascular Disease.
    Estrella MM; Parekh RS
    Semin Nephrol; 2017 Nov; 37(6):520-529. PubMed ID: 29110759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial.
    Langefeld CD; Divers J; Pajewski NM; Hawfield AT; Reboussin DM; Bild DE; Kaysen GA; Kimmel PL; Raj DS; Ricardo AC; Wright JT; Sedor JR; Rocco MV; Freedman BI;
    Kidney Int; 2015 Jan; 87(1):169-75. PubMed ID: 25029429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.
    Gutiérrez OM; Judd SE; Irvin MR; Zhi D; Limdi N; Palmer ND; Rich SS; Sale MM; Freedman BI
    Nephrol Dial Transplant; 2016 Apr; 31(4):602-8. PubMed ID: 26152403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population-based risk assessment of APOL1 on renal disease.
    Friedman DJ; Kozlitina J; Genovese G; Jog P; Pollak MR
    J Am Soc Nephrol; 2011 Nov; 22(11):2098-105. PubMed ID: 21997396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apolipoprotein L1 Genotypes and the Association of Urinary Potassium Excretion with CKD Progression.
    Ilori TO; Liu J; Rodan AR; Verma A; Mills KT; He J; Winkler CA; Dupuis J; Anderson CAM; Waikar SS
    Clin J Am Soc Nephrol; 2022 Oct; 17(10):1477-1486. PubMed ID: 36400568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Race, APOL1 Risk, and eGFR Decline in the General Population.
    Grams ME; Rebholz CM; Chen Y; Rawlings AM; Estrella MM; Selvin E; Appel LJ; Tin A; Coresh J
    J Am Soc Nephrol; 2016 Sep; 27(9):2842-50. PubMed ID: 26966015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemostatic Factors, APOL1 Risk Variants, and the Risk of ESRD in the Atherosclerosis Risk in Communities Study.
    Tin A; Grams ME; Maruthur NM; Astor BC; Couper D; Mosley TH; Fornage M; Parekh RS; Coresh J; Kao WH
    Clin J Am Soc Nephrol; 2015 May; 10(5):784-90. PubMed ID: 25887069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apolipoprotein L1 High-Risk Genotypes and Albuminuria in Sub-Saharan African Populations.
    Brandenburg JT; Govender MA; Winkler CA; Boua PR; Agongo G; Fabian J; Ramsay M
    Clin J Am Soc Nephrol; 2022 Jun; 17(6):798-808. PubMed ID: 35577564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma biomarkers are associated with renal outcomes in individuals with APOL1 risk variants.
    Nadkarni GN; Chauhan K; Verghese DA; Parikh CR; Do R; Horowitz CR; Bottinger EP; Coca SG
    Kidney Int; 2018 Jun; 93(6):1409-1416. PubMed ID: 29685497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein L1 Genetic Variants Are Associated with Chronic Kidney Disease but Not with Cardiovascular Disease in a Population Referred for Cardiac Catheterization.
    Wang H; Pun PH; Kwee L; Craig D; Haynes C; Chryst-Ladd M; Svetkey LP; Patel UD; Hauser ER; Pollak MR; Kraus WE; Shah SH
    Cardiorenal Med; 2017 Feb; 7(2):96-103. PubMed ID: 28611783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum 6-Bromotryptophan Levels Identified as a Risk Factor for CKD Progression.
    Tin A; Nadkarni G; Evans AM; Winkler CA; Bottinger E; Rebholz CM; Sarnak MJ; Inker LA; Levey AS; Lipkowitz MS; Appel LJ; Arking DE; Coresh J; Grams ME
    J Am Soc Nephrol; 2018 Jul; 29(7):1939-1947. PubMed ID: 29777021
    [No Abstract]   [Full Text] [Related]  

  • 40. Dietary Patterns, Apolipoprotein L1 Risk Genotypes, and CKD Outcomes Among Black Adults in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study.
    Ilori TO; Brooks MS; Desai PN; Cheung KL; Judd SE; Crews DC; Cushman M; Winkler CA; Shlipak MG; Kopp JB; Naik RP; Estrella MM; Gutiérrez OM; Kramer H
    Kidney Med; 2023 May; 5(5):100621. PubMed ID: 37229446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.